Taisho To Enter Lactic Acid Market With Biofermin Acquisition
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Taisho Pharmaceutical will take its first steps into the lactic acid bacteria drugs market following its proposed acquisition of Kobe, Japan-based Biofermin Pharmaceutical, approved by the latter's board Feb. 12
You may also be interested in...
Analysis: Film-Maker Fujifilm To Enter Japan Drug Business with Toyama Chemical Acquisition
Fujifilm Holdings' bid to buy Toyama Chemical signals a move by companies with technologies beneficial to drug making to enter the pharmaceutical market. Ajinomoto, in the seasoning and food business, relies on fermentation technologies for its amino acid-based drugs, and Toray Industries applies biotechnology and nanotechnology to help develop drugs with long-lasting effects. Japan Pharmaceutical Manufacturers Association President Hatsuo Aoki said his industry expects to see an increase in mergers and acquisitions centered on certain technologies rather than company size. (Click here for more - a subscription may be required
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
Need a specific report? 1000+ reports available
Buy Reports